In this issue:
Deep learning approach to predict SLN status from histology of primary melanoma tumours
Validation of a nomogram to predict SN positivity in patients with melanoma
Histopathologic synoptic reporting of invasive melanoma
Lifileucel in metastatic melanoma
Pembrolizumab + ipilimumab following anti-PD-1/L1 failure in melanoma
Pyrexia in patients treated with dabrafenib + trametinib in BRAFmutant cancers
Ceralasertib, a novel DDR, plus paclitaxel in refractory cancer
LPV7 + TLR agonists with or without IFA for resected high-risk melanoma
Citrus consumption and melanoma risk
Melanoma surveillance using the MoleMap NZ telemedicine platform
Please login below to download this issue (PDF)